ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Labs 1Q Net Rose 44% On Strong Drug, Nutritional Sales

DOW JONES NEWSWIRES Abbott Laboratories' (ABT) first-quarter earnings rose 44% as strong drug and nutritional sales contributed to improved margins. The health-care company also raised its full-year earnings guidance by 5 cents, now projecting $5 to $5.10 a share. Abbott's diverse portfolio had cushioned it from some of the problems, like patent expirations and generic competition, facing other large drug makers. But its bottom-line performance has been mixed in recent quarters as restructuring and acquisition charges masked revenue growth. The company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating its proprietary drug unit and medical products business into two publicly traded companies by the end of this year. Last month, Abbott named its post-spinoff pharmaceutical company AbbVie, in a nod to the new company's origins and purpose. The health-care company said the name is derived from a combination of Abbott and vie, which references the Latin root vi, meaning life. Abbott Labs reported a profit of $1.24 billion, or 78 cents a share, up from $864 million, or 55 cents, a year earlier. Excluding items such as restructuring, acquisition and integration costs, earnings rose to $1.03 a share from 91 cents. Sales jumped 4.6% to $9.46 billion. Analysts polled by Thomson Reuters had most recently forecast earnings of $1 a share on revenue of $9.37 billion. Operating margin rose to 16.7% from 14.4%. Proprietary pharmaceutical sales, the company's biggest segment by revenue, rose 7.1%. Nutritional sales, which include Similac and Ensure, grew 10%. The established products segment, which focuses on generic sales outside the U.S., saw a 1.6% sales decline. Core laboratory diagnostics sales were up 4.9%. Shares closed Tuesday at $60.43 and were inactive premarket. The stock has gained 9.2% over the past three months. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
06/24/201617:11:17Annual Report of Employee Stock Plans (11-k)
06/22/201609:00:00Abbott Hosts Conference Call for Second-Quarter Earnings
06/17/201617:06:51Statement of Changes in Beneficial Ownership (4)
06/17/201617:05:34Statement of Changes in Beneficial Ownership (4)
06/13/201617:30:36Securities Registration: Business Combination (s-4)
06/13/201609:00:00Abbott Announces Positive Results from Groundbreaking Study of...
06/10/201611:05:00Abbott Declares 370th Consecutive Quarterly Dividend
06/09/201602:00:15Aqua Bio Technology: Aqua Bio Technology ASA ex-dividend of NOK...
06/08/201618:00:00AmSurg, Envision Healthcare Hold Merger Talks
06/08/201608:54:39Aqua Bio Technology: Ordinary general meeting held on 8 June...
06/07/201609:16:18ABT: Update on U.S. lawsuit
06/06/201612:20:00Gilead's New CEO Faces Pressures on Hepatitis C Pills
06/03/201617:11:22Statement of Changes in Beneficial Ownership (4)
06/03/201617:10:55Statement of Changes in Beneficial Ownership (4)
06/03/201617:10:30Statement of Changes in Beneficial Ownership (4)
05/31/201611:04:47Specialized Disclosure Report (sd)
05/13/201601:35:19Aqua Bio Technology: Key information relating to cash dividend...
05/13/201601:30:42Aqua Bio Technology: Notice of annual general meeting
05/11/201602:01:10Good first quarter for Aqua Bio Technology
05/10/201612:41:00New Curate™ Kids Combines Wholesome Ingredients and Kid-Friendly F...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad